EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Daniel Wolff, Corey Cutler iD, Stephanie J Lee, Iskra Pusic, Henrique Bittencourt, Jennifer White, Mehdi Hamadani, Sally Arai, Amandeep Salhotra, Jose A Perez-Simon, Amin Alousi, Hannah Choe und 12 weitere

New England Journal of Medicine · 19.09.2024 · 391 (11) · 1002-1014

DOI: 10.1056/nejmoa2401537 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.09.2024. Verfasst von Daniel Wolff und 23 weiteren Autor:innen. Beteiligte Einrichtung: From University Hospital Regensburg, Regensburg, Germany (D.W.); Dana-Farber Cancer Institute and Harvard Medical School (C.C.) and Massachusetts Gen…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Receptor, Macrophage Colony-Stimulating Factor. Die Arbeit wurde bisher 168-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGraft vs Host DiseaseHematopoietic Stem Cell TransplantationReceptor, Macrophage Colony-Stimulating FactorAdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedYoung AdultChronic DiseaseDose-Response Relationship, DrugInfusions, IntravenousRecurrenceSeverity of Illness IndexTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedaxatilimabCSF1R protein, humanReceptor, Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • From University Hospital Regensburg, Regensburg, Germany (D.W.); Dana-Farber Cancer Institute and Harvard Medical School (C.C.) and Massachusetts General Hospital (Z.D.), Boston, and Syndax Pharmaceuticals, Waltham (V.R…

ORCID-Profile: Corey Cutler, Vedran Radojcic

Zitieren

APA

Wolff, D., Cutler, C., Lee, S. J., Pusic, I., Bittencourt, H., White, J., Hamadani, M., Arai, S., Salhotra, A., Perez-Simon, J. A., Alousi, A., Choe, H., Kwon, M., Bermúdez, A., Kim, I., Socié, G., Chhabra, S., Radojcic, V., O'Toole, T., …, & AGAVE-201 Investigators (2024). Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. New England Journal of Medicine, 391(11), 1002-1014. https://doi.org/10.1056/nejmoa2401537

Vancouver

Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. New England Journal of Medicine. 2024;391(11):1002-1014. doi:10.1056/nejmoa2401537

BibTeX
@article{Wolff2024,
  author = {Wolff, Daniel and Cutler, Corey and Lee, Stephanie J and Pusic, Iskra and Bittencourt, Henrique and White, Jennifer and Hamadani, Mehdi and Arai, Sally and Salhotra, Amandeep and Perez-Simon, Jose A and Alousi, Amin and Choe, Hannah and Kwon, Mi and Bermúdez, Arancha and Kim, Inho and Socié, Gerard and Chhabra, Saurabh and Radojcic, Vedran and O'Toole, Timothy and Tian, Chuan and Ordentlich, Peter and DeFilipp, Zachariah and Kitko, Carrie L and AGAVE-201 Investigators, AGAVE-201 Investigators},
  title = {Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {11},
  pages = {1002--1014},
  doi = {10.1056/nejmoa2401537}
}
Kostenlos starten →